scroll down

Chemesis International Inc. Provides Corporate Update 

VANCOUVER, BC, ACCESSWIRE / September 2, 2020 / Chemesis International Inc. (CSE:CSI) (OTCQB:CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), is pleased to announce that the Puerto Rico cannabis licenses (the “Licenses”) held by the Company’s subsidiary, Natural Ventures PR LLC, have been granted an administrative extension for a period of sixty (60) days by the Department of Health of Puerto Rico. The Company notes that the Licenses have, as a matter of routine, been extended on such basis every sixty (60) days during the period in which the status of the Licenses has been subject to an appeal before the courts in Puerto Rico.

On Behalf of The Board of Directors
Josh Rosenberg

About Chemesis International Inc.

Chemesis focuses on prudent capital allocations to ensure it maintains second mover advantage as it enters new markets with a proven lift & shift consumer focused model deployed with the objective a being #1 or a strong #2 in every market in which we compete. Chemesis leverages a portfolio of strong consumer brands to recruit, retain, & grow share of wallet with a proven consumer loyalty platform. Chemesis is focused on scalable growth within our business operations through disciplined investment of both insource and outsourced levers to maximize use of capital. This includes our retail strategy of coalescing dispensary and alternative route to market.

Chemesis and its team are committed to building a strong unattended and attended retail model for the cannabis market across the United States and Puerto Rico. Chemesis’ retail brand, Green Spirit Rx, will continue to provide consumers with industry-leading technology, the most sought-after products and continued education.  

Investor Relations:

[email protected]
1 (604) 398-3378

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the potential or ability for the Company to commence any Further Appeals and the ability of the Company to continue to operate under the Licenses.  Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements including, among other things, the risks that the Company will not be able to commence a Further Appeal in a timely manner, or at all, that the Company will not be able to maintain or continue licensed activities under the Licences as currently being conducted, or at all, and that the Company’s products and plans will vary significantly as a result. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release


Historical Press Releases
This website contains historical and archived press releases for Chemesis International (“Chemesis”). The information in these press releases is historical in nature, has not been updated, and is current only to the date as indicated in the press release.